Detlev Hartz

Learn More
Glimepiride is a novel sulfonylurea for the treatment of type II-diabetic patients exhibiting different receptor binding kinetics to B-cell membranes with 8-9-fold higher kof f rate and 2.5-3-fold higher kon rate compared to glibenclamide (see accompanying paper (Miiller, G. et al. (1994) Biochim. Biophys. Acta 1191, 267-277)). To elucidate the molecular(More)
Glimepiride is a novel sulfonylurea drug for treatment of non-insulin-dependent diabetes mellitus with higher blood sugar lowering efficacy in diabetic patients than glibenclamide raising the question whether this characteristics is in line with different binding of glimepiride and glibenclamide to the beta-cell sulfonylurea receptor. Scatchard plot(More)
  • 1